Trial Profile
An Open label, International, Multicenter, Dose Escalating Phase 1/2 Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genmab; Janssen Research & Development; Janssen-Cilag
- 30 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.
- 10 Oct 2023 Planned End Date changed from 31 Dec 2025 to 1 Jan 2024.
- 06 Dec 2021 This trial has been completed in Netherland, according to European Clinical Trials Database record.